Carvin is a global Biopharmaceutical Company
411 University St, Seattle, USA
engitech@oceanthemes.net
+1 -800-456-478-23
In Exclusive Partnership with 37-year old Swiss Pharma company, Alpex Pharma S.A., we are developing FDA and EMA approved drugs and treatment protocols, and leveraging manufacturing expertise by to streamlining formulation, stability, regulatory requirements, and drug registration. Our formulations are designed to mitigate common side effects and improve the drug efficacy by pairing APIs with our patented delivery technologies.
With unmet patient needs that are typically treated by Opiates, SSRIs, SDRIs, and SNRIs.
Intellectual Property based on proprietary formulations and delivery technologies for optimum efficacy and success.
In full control of the drug development life cycle with immediate capacity to scale and deploy for Clinical Trials and Commercialization.
Developing medicines and regiments with existing psychedelic compounds for chronic administration.
Patented technologies for optimum drug delivery resulting in faster onset, safety and tolerability.
Proprietary regimen of micro and low dose formulations eliminate perceptual any physical side effects.
Targeted modality of drug administration that is designed to reach the therapeutic objective for treatment of neurogenic disease.
Carvin initiates project, and self funds drug development, and fully owns IP. Alpex then licenses to partners for marketing, sales and distribution in global markets.
Partners initiate project with concept and desired API. Alpex develops and commercializes the product. Partner handles marketing, sales & distribution in target markets.
Carvin provides full contract development and manufacturing service for every aspect of drug development and manufacturing in a client-fee commercial relationship.
